Robert Carroll
Partner, Head of Investor Relations, ESG and Impact, Sofinnova Partners
Rob joined us in January 2020 from PwC’s Global Fundraising Advisory Platform, which he helped establish and co-led. He leads investor relations and our responsible investment strategy.
Rob has almost 15 years of experience working with institutional investors and raising capital for alternative assets.
Prior to PwC, he was at Mercury Capital Advisors, a global private fundraising and investment advisory firm that has its origins in Merrill Lynch. At Mercury, he supported the needs of institutional investors and successfully raised capital across the alternative assets spectrum.
Prior to his career in private placement, Rob worked as a Principal Scientist and project lead at Pfizer, working on products from discovery through pre-clinical and into clinical development. He has also worked at GSK and Eli Lilly.
Rob holds a PhD in chemistry (Prof. Willie Motherwell, University College London) and completed postdoctoral research at Brock University, Canada in the labs of Prof. Tomáš Hudlický, with a focus on the semi-synthesis of morphine and its analogues. This work was carried out in collaboration with Noramco (then a part of Johnson & Johnson) and is the subject of a number of patents.
"An active, evolving, innovative approach to ESG is a new way of creating value in a company, and if you are not doing it, clearly, you will be missing out. Investors, investees and acquirers will expect it."
